On January 4, 2021 Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) reported that management will present at the 40th Annual J.P. Morgan Healthcare Conference on Monday, January 10, 2022 at 9:00 a.m. ET (Press release, Vertex Pharmaceuticals, JAN 4, 2022, View Source [SID1234598250]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast of management’s remarks will be available through Vertex’s website, www.vrtx.com in the "Investors" section under the "News and Events" page. A replay of the conference webcast will be archived on the company’s website.

On January 4, 2022 ChemoCentryx, Inc., (Nasdaq: CCXI), reported that Thomas J. Schall, Ph.D., President and Chief Executive Officer, will present at two upcoming investor conferences (Press release, ChemoCentryx, JAN 4, 2022, View Source [SID1234598247]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

40th Annual J.P. Morgan Healthcare Conference
Wednesday, January 12 at 4:30 p.m. Eastern Time
H.C. Wainwright Virtual BioConnect Conference
On-demand presentation available beginning Monday, January 10 at 7:00 a.m. Eastern Time
A live audio webcast of the J.P. Morgan presentation, as well as the on-demand H.C. Wainwright presentation can be accessed through the Investors section of the Company’s website at www.ChemoCentryx.com. Replays of both presentations will be available on the Company’s website for two weeks following the respective presentation dates.

On January 4, 2022 Labcorp (NYSE: LH), a leading global life sciences company, reported that members of the executive management team will participate in a virtual fireside chat at the 40th Annual J.P. Morgan Healthcare Conference on Tuesday, Jan. 11 at 4:30 p.m (ET) (Press release, LabCorp, JAN 4, 2022, View Source [SID1234598228]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast of the presentation will be available via the Company website at www.Labcorp.com and archived for replay.

On January 4, 2022 4D pharma plc (AIM: DDDD, NASDAQ: LBPS), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs), a novel class of drug derived from the microbiome, reported that share options ("Options") have been granted to certain executive directors and members of the senior management team of the Company to acquire a total of 7,278,958 ordinary shares of 0.025p each ("Ordinary Shares") in the Company under the 4D Pharma plc Long Term Incentive Plan with an exercise price of 53.6 pence, being the closing mid-price on 31 December 2021 (Press release, 4d Pharma, JAN 4, 2022, View Source [SID1234598193]). Further details are set out in the table below. The Company may opt to issue ADSs rather than Ordinary Shares upon exercise, in accordance with the 8:1 ratio of Ordinary Shares to ADSs.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

In order to attract and retain personnel necessary to promote the success of the Company for the benefit of its members as a whole, the Company’s Board of Directors instructed that an external, independent benchmarking exercise should be undertaken to ensure that the Company’s remuneration of its employees was comparable to that of its Nasdaq-listed peer group.

Factoring in the results of this benchmarking exercise, and also taking into account that since formation of the Company, no company-wide equity awards had been made previously (including in relation to executive board directors), the Company decided to award share options to all qualifying employees. On 17 December 2021, options were granted to such employees to acquire a total of 7,520,152 Ordinary Shares with an exercise price of 52.35 pence, being equal to the closing mid-price on the date of grant. Together with the 7,278,958 Options granted today, a total of 14,799,110 Options have been granted, representing 8.21 per cent. of the Company’s issued share capital.

The Options awarded today vest in equal parts annually over a period of four years, beginning on 1 June 2022, save for John Doyle where vesting starts from 3 January 2023, and are exercisable over a period of 10 years from the date of grant.

The information set out below is provided in accordance with the requirements of Article 19(3) of the EU Market Abuse Regulation No 596/2014.

On January 4, 2022 TG Therapeutics, Inc. (NASDAQ: TGTX), reported that its existing term loan facility agreement with Hercules Capital, Inc. (NYSE: HTGC), has been amended to increase the size of the facility to $200 million, with $70 million funded at closing (Press release, TG Therapeutics, JAN 4, 2022, View Source [SID1234598168]). Michael S. Weiss, Chairman and Chief Executive Officer of TG Therapeutics stated, "We are pleased to announce the expansion of our term loan facility with Hercules Capital and the immediate draw of $70 million. Hercules has been a great partner of ours, and we believe this expansion provides us with the financial flexibility we need in the short-term. With the funds immediately drawn we strengthened our year-end 2021 balance sheet and believe we are now positioned well financially."

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Michael Dutra, Managing Director at Hercules Capital shared, "Hercules is excited to continue and expand our partnership with TG Therapeutics as they advance their pipeline and work to bring their treatments to patients. The new increased commitment from Hercules exemplifies our ability to be long-term capital partners to our portfolio companies and reflects our dedication to financing innovative life sciences companies through development and into commercialization."

Under the terms of the amendment, the size of the term loan facility was increased to $200 million, with $70 million available and drawn at closing on December 30, 2021. The remaining $130 million may be drawn at the Company’s option, in three subsequent tranches. The first tranche is available upon U.S. Food and Drug Administration (FDA) approval of the supplemental New Drug Application (sNDA)/ Biologics License Agreement (BLA) for the combination of ublituximab and umbralisib (referred to as "U2") for the treatment of chronic lymphocytic leukemia (CLL), the second tranche is available upon FDA approval of the BLA for ublituximab for the treatment of relapsing forms of multiple sclerosis (RMS), and the third tranche is available to fund future initiatives, subject to the approval of the Hercules Investment Committee.

Additional details of the loan amendment will be filed with the Securities and Exchange Commission on Form 8-K.